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CORRESPONDENCE
Letters to the Editor
Heart Failure and Genomics
We applaud the efforts by Drs. Donahue, Marchuk, and Rockman
to review the current utility of genomics in heart failure (1). As
they noted, this is a complex and developing field both in
cardiology and in other medical specialties, with great potential to
enhance our ability to diagnose and treat a variety of major
cardiovascular disorders.
Although the primary focus of their study was not to review the
utility of clinical genetic testing for familial cardiomyopathies,
their strong negative statements need further clarification. In
reference to familial cardiomyopathies, they state, “Given the
current complexity of the field, no clinically useful genetic testing
is available.” In their concluding paragraph, they note, “There is no
current evidence supporting the routine clinical use of genomic
information in the care of patients with cardiomyopathy.”
In the U.S. there are at least 9 clinical genetic laboratories
performing lamin A/C (LMNA) sequencing for several conditions
including familial dilated cardiomyopathy (FDC). As the research-
ers indicate, mutations in LMNA are associated with increased
likelihood of arrhythmia, sudden death, and skeletal myopathy
(2,3). Clinical testing for additional genes associated with FDC is
also available. We believe that identifying a disease-causing mu-
tation in LMNA, or other genes implicated in FDC, is important
to determine which family members are at risk for developing
disease and to allow initiation of treatment at an early, presymp-
tomatic stage of disease.
In contrast to FDC, clinical genetic testing for hypertrophic
cardiomyopathy has even greater likelihood of finding a responsi-
ble mutation (4). The Clinical Laboratory Improvement Amend-
ments (CLIA)-approved Laboratory for Molecular Medicine at
Harvard performs clinical genetic sequencing for eight sarcomere
genes, as well as 2 additional genes for “unexplained hypertrophy.”
When applied appropriately, 50% to 70% of cases will have a
definite or probable disease-causing sarcomere mutation identified.
Clinical genetic testing for arrhythmogenic right ventricular
cardiomyopathy (ARVC) has recently emerged owing to the
prevalence of mutations in the plakophilin-2 gene, PKP2, among
affected individuals (5). Improved recognition of the phenotypic
correlations with mutations in this gene will lead to better
understanding of the implications of a positive genetic test and
assist in the often challenging diagnosis of ARVC (6,7).
Genetic testing is currently available for over a thousand
conditions in the U.S., and its utility is interpreted in different
contexts, including public health, clinical, personal, and social
perspectives (8). Patients identify many reasons why they wish to
proceed with genetic testing, including confirmation of a clinical
diagnosis, presymptomatic identification of at-risk family mem-
bers, and family planning. For many genetic disorders, techniques
such as pre-implantation genetic diagnosis and sperm sorting (for
X-linked conditions) are available. As direct-to-patient advertising
for genetic testing expands to genetic cardiac diseases, a nihilistic
approach to clinical genetic testing for inherited cardiomyopathy
will leave behind physicians who still retain this philosophy (9).
We advocate genetic counseling for all patients with inherited
cardiomyopathies, including discussion of the risks, benefits, lim-
itations, and clinical implications of the possible outcomes of
genetic testing. Only by embracing the appropriate use of clinical
genetic testing will the cardiology community begin to benefit
from advances that have been reached in other fields of medicine.
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Reply
We appreciate the letter from Dr. Judge and colleagues, and we
agree with their assertions that the cardiology community should
be very proactive in the adoption of the advances that genetics
brings to the field. We believe that clinically useful testing
encompasses both the widespread availability of the test (including
the number of laboratories performing the test and cost of the test)
and its clinical utility (the results of the test will influence
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